Archives

When targeting lung tumors there is a risk of exposing upper parts of the heart unnecessarily to toxic levels of radiation. This can potentially be avoided by more bespoke levels of radiation field c

Although breast conserving therapy has proved of equivalent efficacy to mastectomy in many patients with early breast cancer, mastectomy was associated with longer survival among those with HER2 posit

AMSTERDAM, Netherlands—Some patients with breast cancer could soon be treated with surgery and targeted drugs without the need for chemotherapy—according to findings reported at the 2016 European Brea

The Audio Journal of Oncology tracks down the half dozen leading stories breaking in Turin at ESTRO 2016—the annual meeting of the European Society for Radiotherapy and Oncology. Nicolle Rekers MSc.,

BARCELONA—A new pencil beam scanning proton delivery technique—rescanning—could help limit the dose of radiation to surrounding tissues and organs by compensating for tumor motion in the chest caused

BARCELONA—A radiotherapy dose of more than 54 Gy improved survival in children with localized cerebral ependymoma in a large multicenter study from France that looked at the role of age, grade and dos

BARCELONA—For children with intracranial ependymoma and measurable residue after first- or second-line surgery, a hypofractionated radiotherapy boost was feasible and improved local control—in a study

BARCELONA—A sub-group analysis of a phase-III randomized study looking at women with early breast cancer found that patients aged 70 years or older who were treated with accelerated partial breast irr

BARCELONA—In patients with previously irradiated locally recurrent prostate cancer, salvage high-dose-rate brachytherapy (HDRB) was an effective and safe treatment option. The 3rd ESTRO Forum (April 2

BARCELONA—The finding from the phase-III ARCON trial presented at the 3rd ESTRO Forum that: Accelerated radiotherapy with carbogen and nicotinamide (ARCON) significantly improved outcomes for patients

BARCELONA—Accelerated radiotherapy with carbogen and nicotinamide (ARCON) significantly improved regional control while maintaining excellent speech and swallowing for a majority of patients with adva

BARCELONA—There was no improvement in biochemical progression free survival among patients who had their high-risk localized prostate cancers treated with elective pelvic nodal irradiation compared wi

BARCELONA – For patients with locally advanced cervical cancer, combining intracavitary and interstitial (IC/IS) brachytherapy techniques should be the benchmark treatment. That’s accordin

BARCELONA – The 3rd European Society for Radiotherapy & Oncology Forum — ESTRO — was held this year in Barcelona featuring all aspects of the radiation oncology field. Oncology Times report

BARCELONA—Men with intermediate- or high-risk prostate cancer who were treated with low dose rate prostate brachytherapy (LDR-PB) were twice as often cancer-free at five years compared to those given

BARCELONA – Brachytherapy with or without external beam radiation improved survival in patients with early-stage, inoperable endometrial cancer. That’s according to findings of a populatio

GENEVA— The IGNITE study from Chinese researchers has demonstrated how plasma—and not just tissue samples—could be used to distinguish patients with non-small cell lung cancer who could benefit from E

GENEVA—An alternative way of testing for mutated EGFR in patients with advanced non-small cell lung cancer was validated in research presented at the European Lung Cancer Conference by Martin Reck MD

GENEVA— Almost one in four patients with advanced lung cancer in Europe, Asia and the US are not receiving EGFR test results before being started on treatment—according to a report presented at the Eu

GENEVA—Findings from the retrospective EURAF study suggest that many patients with BRAF-mutant lung cancers could benefit from treatment with BRAF inhibitors, although specific studies need to be done

GENEVA—Two thirds of patients with advanced non-small cell lung cancer that had failed first line anti-EGFR therapy responded to a new drug: AZD9291 according to findings discussed at the European Lun

GENEVA—Reviews of CD8-positive T-cell infiltration as an independent prognostic biomarker in resected non-small cell lung cancer, and the potential of checkpoint inhibitor therapy for mesothelioma aft

GENEVA—First or second-line chemotherapy with cisplatin-pemetrexed or gemcitabine does not preclude the use of checkpoint inhibitor therapy for mesothelioma later on—according to research presented at

GENEVA—The use of combinations including checkpoint inhibition with other immunotherapies, other targeted therapies and chemotherapy was discussed at the European Lung Cancer Conference by Martin Reck

GENEVA—The recent success of treatment with immune checkpoint inhibitors suggests that immunotherapy could presently move center stage to play a leading role in fighting non-small cell lung cancer—the